Press release
Regulated information
3 October 2019, 7 a.m. CEST
IRVINE, CA, and HERSTAL, BELGIUM – 3 October 2019 – MDxHealth SA (Euronext Brussels: MDXH) (the “Company” or "MDxHealth"), a commercial-stage innovative molecular diagnostics company, announced that it received the following notification of a significant shareholding in accordance with the Belgian Act of 2 May 2007 on the disclosure of important participations in issuers of which shares are admitted to trading on a regulated market and regarding miscellaneous provisions.
Scorpiaux BVBA notified MDxHealth of the acquisition of voting rights attached to securities in MDxHealth, as a result of which, on 27 September 2019, its participation in MDxHealth increased above the threshold of 5% of the outstanding shares and voting rights of MDxHealth. Notably, it follows from the notification that Scorpiaux BVBA owns 3,867,776 shares of MDxHealth, representing 5.48% of the 70,528,525 outstanding shares and voting rights of MDxHealth. The notification states that Scorpiaux BVBA is exclusively controlled by Bart Versluys in the sense of articles 5 and 7 of the Belgian Companies Code, and that Scorpiaux BVBA, together with a third party, has control, in the sense of articles 5 and 7 of the Belgian Companies Code, over Versluys Invest BVBA.
For further information, reference is made to the information published on MDxHealth's website (http://www.mdxhealth.com/investors/shareholder-information).
About MDxHealth®
MDxHealth is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. The Company's tests are based on proprietary genetic, epigenetic (methylation) and other molecular technologies and assist physicians with the diagnosis of urologic cancers, prognosis of recurrence risk, and prediction of response to a specific therapy. The Company's European headquarters are in Herstal, Belgium, with laboratory operations in Nijmegen, The Netherlands, and US headquarters and laboratory operations based in Irvine, California. For more information, visit mdxhealth.com and follow us on social media at: twitter, facebook and linkedin.
For more information:
Amber Fennell, Chris Welsh, Nicholas Brown
Consilium Strategic Communications
UK: +44 20 3709 5700
mdxhealth@consilium-comms.com
Important Information:
The MDxHealth logo, MDxHealth, ConfirmMDx and SelectMDx are trademarks or registered trademarks of MDxHealth SA (the "Company" or " MDxHealth"). All other trademarks and service marks are the property of their respective owners.
Attachment
